U.S. House Defense and Small Business Lawmaker Bets Millions on AI Semiconductors and Medical Devices
According to a June 8 financial disclosure filed with the U.S. House of Representatives, Democratic Representative Gilbert Cisneros of California’s 31st District made multiple stock purchases in May of AI-semiconductor leader Advanced Micro Devices (AMD) and medical-device maker Boston Scientific. Each transaction was reported in the $1,001–$15,000 range (approximately ₩1.3 million–₩20 million); given the repeated buys, his total investment per company may have reached tens of millions of won.
A former U.S. Navy officer, Cisneros returned to Congress in 2025 and now serves on both the House Armed Services Committee and the Small Business Committee. On Armed Services, he sits on the Intelligence & Special Operations and Military Personnel subcommittees; on Small Business, he serves on Contracting & Infrastructure and Oversight & Investigations. In these roles he influences defense technology procurement, small-business supply chains, and healthcare and welfare budgets. His direct investments in AMD—key to U.S. defense and AI supply chains—and in Boston Scientific—which supplies devices used in Medicare, military and veterans’ healthcare—have raised potential conflict-of-interest concerns and could intensify congressional calls for tighter restrictions on individual members’ stock trading.
AMD has been hailed as an “AI infrastructure” beneficiary: in the first quarter of fiscal 2026 (ended March), revenue jumped 38% year-over-year, driven by strong demand for EPYC server CPUs and Instinct AI accelerators, with data-center revenue alone hitting $5.8 billion. On May 14, the date Cisneros first reported a purchase, AMD closed around $449. Fueled by growing AI-server investment expectations and news of a ramp-up in next-generation 2 nm EPYC “Venice” production, shares rose to about $490 in early June, offering roughly a 10% unrealized gain on his initial price bracket. Given the stock’s 300%+ surge over the past year and its volatility, a member of Congress overseeing defense and intelligence policy betting tens of thousands of dollars on a single AI-semiconductor stock could underscore “information advantage” concerns and complicate upcoming legislative debates on semiconductor and AI regulation and subsidies.
Boston Scientific is a leading med-tech company producing cardiovascular-intervention, electrophysiology, neuromodulation, and other devices. Its first-quarter 2026 revenue grew about 11–12% year-over-year. Cisneros’s first buy on May 11 was at roughly $53 per share; however, when management lowered its 2026 organic-growth guidance to 6.5–8% and forecast Q2 growth of 5–7% at a late-May investor conference, the stock plunged nearly 10% in one day and has since given back almost half of its March 52-week high near $70. Amid a valuation reset driven by concerns over reduced procedure demand due to GLP-1 obesity and diabetes drugs, pricing-regulation risk, and litigation exposure, Cisneros’s repeated purchases of Boston Scientific—given his influence over military, veterans and Medicare healthcare budgets—are expected to draw heightened public scrutiny and regulatory review in future legislative and oversight proceedings.